Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer

JAMA

Volumn 307, Issue 15, 2012, Pages 1593-1601

  Zhu, Junya ^a   Sharma, Dhruv B ^a   Gray, Stacy W ^a   Chen, Aileen B ^a   Weeks, Jane C ^a   Schrag, Deborah ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; INCOME; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SURVIVAL TIME; TUMOR DIFFERENTIATION; URBAN POPULATION;

EID: 84859851347     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.454     Document Type: Article

References (37)

1. Iannettoni MD. Staging strategies for lung cancer. JAMA. 2010;304(20):2296-2297.
2. NSCLCMeta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617-4625.
3. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2191-2197.
4. Altekruse SF, Kosary CL, Krapcho M, et al National Cancer Institute. SEER cancer statistics review, 1975-2007. http://seer.cancer.gov/csr/1975-2007/. Accessed August 20, 2011.
5. Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist. 2007;12(10):1183-1193. (Pubitemid 350106349)
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med. 2006;355(24):2542-2550. (Pubitemid 44917502)
7. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/ metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713-718. (Pubitemid 47036205)
8. Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229-241.
9. Ramalingam SS, Dahlberg SE, Langer CJ, et al Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26(1):60-65.
10. Centers for Medicare & Medicaid Services. Medicare National Coverage Determinations Manual: Chapter 1, Part 2 (Sections 90-160.26): Coverage Determinations. https://www.cms.gov/manuals/downloads/ncd103c1-part2.pdf. Accessed September 25, 2011.
11. National Cancer Institute. Surveillance, Epidemiology and End Results. http://seer.cancer.gov. Accessed May 2, 2011.
12. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
13. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-Medicare data to conduct casecontrol studies of cancer among the US elderly. Am J Epidemiol. 2011;174(7):860-870.
14. Greene FL, Page DL, Balch CM, Fleming ID, Fritz AG. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
15. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8)(suppl):IV-55-IV-61.
16. Lamont EB, Herndon JE II, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97(14):1080-1083. (Pubitemid 41417925)
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
19. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267. (Pubitemid 32007842)
20. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584-590. (Pubitemid 47096709)
21. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8)(suppl):IV-19-IV-25.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
23. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516- 524.
24. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA. 2007;297(3):314-316.
25. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763. (Pubitemid 27446562)
26. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
27. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23(19):2937-2960. (Pubitemid 39200133)
28. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560. (Pubitemid 30660034)
29. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
30. Mitka M. Targeted therapies take aim against lung cancer and melanoma. JAMA. 2010;304(6):624-626.
31. Grusenmeyer PA, Gralla RJ. Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2006;24(suppl):18S.
32. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy vs chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836-845.
33. Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood). 2006;25(2):437-443. (Pubitemid 43529552)
34. Jatoi A, Hillman S, Stella P, et al North Central Cancer Treatment Group. Should elderly non-smallcell lung cancer patients be offered elderly-specific trials? results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol. 2005;23(36):9113-9119.
35. Gridelli C, Maione P, Rossi A, et al. Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer. 2009;66(3):282-286.
36. Gridelli C. Treatment of advanced non-smallcell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol. 2008; 26(1):13-15.
37. Merza T, Howard LM, Junagadhwalla M. Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2007;25(suppl):687S.